Literature DB >> 21703910

Role of microRNA-155 in autoimmunity.

Rui-Xue Leng1, Hai-Feng Pan, Wei-Zi Qin, Gui-Mei Chen, Dong-Qing Ye.   

Abstract

MicroRNAs (miRNAs) have recently emerged as a major class of gene expression regulators linked to most biological functions. MiR-155 is encoded within a region known as B cell integration cluster (Bic) gene, identified originally as a frequent integration site for the avian leukosis virus. Disregulation of endogenous miR-155 has been implicated in the pathogenesis of human cancers. Recently, aberrant expression of miR-155 was observed in many autoimmune conditions, including rheumatoid arthritis (RA), multiple sclerosis (MS), and systemic lupus erythematosus (SLE). Moreover, functional analysis demonstrated that miR-155 has powerful regulatory potential in a wide variety of immune cells through targeting specific mRNAs. Since pathogenic immune cells play a pivotal role in pathogenesis of human autoimmune diseases, miR-155 might be a versatile therapeutic target. This review will discuss the current understandings for the role of miR-155 in autoimmunity.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21703910     DOI: 10.1016/j.cytogfr.2011.05.002

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  59 in total

1.  Is serum microRNA better specific marker for systemic lupus erythematosus?

Authors:  Man-Man Lu; Rui-Xue Leng; Wang-Dong Xu; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2012-05-25       Impact factor: 2.980

Review 2.  Role of miR-155 in the regulation of lymphocyte immune function and disease.

Authors:  Nabila Seddiki; Vedran Brezar; Nicolas Ruffin; Yves Lévy; Sanjay Swaminathan
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

3.  MicroRNA-155 a new therapeutic target in crescentic GN.

Authors:  Stephen R Holdsworth; Shaun A Summers
Journal:  J Am Soc Nephrol       Date:  2013-10-24       Impact factor: 10.121

4.  Tissue-specific production of MicroRNA-155 inhibits melanocortin 5 receptor-dependent suppressor macrophages to promote experimental autoimmune uveitis.

Authors:  Fauziyya Muhammad; Anna Trivett; Dawei Wang; Darren J Lee
Journal:  Eur J Immunol       Date:  2019-06-19       Impact factor: 5.532

5.  Integrated analysis of microRNAs and their disease related targets in the brain of mice infected with West Nile virus.

Authors:  Mukesh Kumar; Vivek R Nerurkar
Journal:  Virology       Date:  2014-01-31       Impact factor: 3.616

Review 6.  Translating the Untranslated Region.

Authors:  Johannes Schwerk; Ram Savan
Journal:  J Immunol       Date:  2015-10-01       Impact factor: 5.422

7.  A myelopoiesis gene signature during remission in anti-neutrophil cytoplasm antibody-associated vasculitis does not predict relapses but seems to reflect ongoing prednisolone therapy.

Authors:  T Kurz; M Weiner; C Skoglund; S Basnet; P Eriksson; M Segelmark
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

8.  A multi-epitope vaccine CTB-UE relieves Helicobacter pylori-induced gastric inflammatory reaction via up-regulating microRNA-155 to inhibit Th17 response in C57/BL6 mice model.

Authors:  Xiaobo Lv; Hui Song; Jue Yang; Tong Li; Tao Xi; Yingying Xing
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

9.  Survival of autoreactive T lymphocytes by microRNA-mediated regulation of apoptosis through TRAIL and Fas in type 1 diabetes.

Authors:  V M de Jong; A R van der Slik; S Laban; R van 't Slot; B P C Koeleman; A Zaldumbide; B O Roep
Journal:  Genes Immun       Date:  2016-07-28       Impact factor: 2.676

10.  Potential role of human-specific genes, human-specific microRNAs and human-specific non-coding regulatory RNAs in the pathogenesis of systemic sclerosis and Sjögren's syndrome.

Authors:  Sergio A Jimenez; Sonsoles Piera-Velazquez
Journal:  Autoimmun Rev       Date:  2013-05-15       Impact factor: 9.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.